Peer-reviewed veterinary case report
New cancer treatment for dogs and cats with soft tissue sarcoma
By Onoyama, Masaki et al.·Published in Journal of veterinary science·2014·Yamaguchi University, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Photodynamic hyperthermal chemotherapy with indocyanine green: a novel cancer therapy for 16 cases of malignant soft tissue sarcoma.
Plain-English summary
Ten dogs and six cats with malignant soft tissue sarcoma (a type of cancer) were treated with a new therapy that combined light treatment, heat, and local chemotherapy after their tumors were surgically removed. This approach, called photodynamic hyperthermal chemotherapy (PHCT), was given multiple times over a few weeks. Remarkably, none of the pets experienced severe side effects, and many showed promising results, with 70% of dogs and 50% of cats not having any cancer return during follow-up periods of up to over five years. This suggests that PHCT could be a helpful option for pets with this type of cancer.
People also search for: dog soft tissue sarcoma treatment · cat cancer therapy options · photodynamic therapy for pets · chemotherapy side effects in dogs and cats
Abstract
Sixteen cases of malignant soft tissue sarcoma (STS; 10 canines and six felines) were treated with a novel triple therapy that combined photodynamic therapy, hyperthermia using indocyanine green with a broadband light source, and local chemotherapy after surgical tumor resection. This triple therapy was called photodynamic hyperthermal chemotherapy (PHCT). In all cases, the surgical margin was insufficient. In one feline case, PHCT was performed without surgical resection. PHCT was performed over an interval of 1 to 2 weeks and was repeated three to 21 times. No severe side effects, including severe skin burns, necrosis, or skin suture rupture, were observed in any of the animals. No disease recurrence was observed in seven out of 10 (70.0%) dogs and three out of six (50.0%) cats over the follow-up periods ranging from 238 to 1901 days. These results suggest that PHCT decreases the risk of STS recurrence. PHCT should therefore be considered an adjuvant therapy for treating companion animals with STS in veterinary medicine.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24136207/